Director/PDMR Shareholding

RNS Number : 3299W

Abingdon Health PLC

21 December 2021

 

21 December 2021

Abingdon Health plc

("Abingdon" or "the Company")

Director/PDMR Dealings

York, U.K. 21 December 2021: Abingdon Health plc (AIM: ABDX), a leading international developer and manufacturer of high quality and effective rapid tests, confirms the participation of certain Directors in the Second Placing, pursuant to the Fundraising announced on 1 December 2021.

Director Participation in the Placing

Participating Director	Number of Existing Ordinary Shares	Number of Placing Shares subscribed for in the Placing	Number of Ordinary Shares held following Second Admission	Percentage of Enlarged Share Capital on Admission
Dr Christopher Hand	11,228,868	999,599	12,228,467	10.0%
Chris Yates	6,513,844	1,000,000	7,513,844	6.2%

Concert Party Interests

Following completion of the Fundraising, the interests of the Concert Party have reduced to 35.8 per cent. of the Company's total voting rights.

Capitalised terms used in this announcement shall have the same meanings as defined in the Circular sent to Shareholders and available to view on the Company's website, as published by the Company on 2 December 2021.

Enquiries:

Abingdon Health plc			www.abingdonhealth.com/investors/
Chris Yates,  Chief Executive Officer			Via Walbrook PR
Melanie Ross , Chief Financial Officer
Christopher Hand,  Non-Executive Chairman
Singer Capital Markets (Sole Broker and Nominated Adviser)			Tel: [phone]
Shaun Dobson, Peter Steel, Alex Bond (Corporate Finance)
Tom Salvesen (Corporate Broking)
Walbrook PR Limited		Tel: [phone] or  [e-mail]
Paul McManus / Phillip Marriage	Mob: [phone]
Alice Woodings	Mob: [phone]

About Abingdon Health

Abingdon Health is a world leading developer and manufacturer of high-quality rapid tests across all industry sectors, including healthcare and COVID-19. Abingdon is the partner of choice for a growing global customer base and takes projects from initial concept through to routine and large-scale manufacturing and has also developed and marketed its own labelled tests.

The Company offers product development, regulatory support, technology transfer and manufacturing services for customers looking to develop new assays or transfer existing laboratory-based assays to a lateral flow format.  Abingdon Health aims to support the increase in need for rapid results across many industries and locations and produces lateral flow tests in areas such as infectious disease, clinical testing including companion diagnostics, animal health and environmental testing. Faster access to results allows for rapid decision making, targeted intervention and can support better outcomes. This ability has a significant role to play in improving life across the world. To support this aim Abingdon Health has also developed AppDx^®, a customisable image capturing technology that transforms a smartphone into a self-sufficient, standalone lateral-flow reader.

 Founded in 2008, Abingdon Health is headquartered in York, England.

  For more information visit:  www.abingdonhealth.com

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them:

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Chris Yates
2	Reason for the notification
a)	Position/status	Chief Executive Officer
b)	Initial notification /Amendment	Initial Notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Abingdon Health plc
b)	LEI	213800XFI4WV3FBILO20
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument	Ordinary Shares of 0.025 pence each
	Identification code	GB00BLF79J41
b)	Nature of the transaction	Purchase of Ordinary Shares
c)	Price(s) and volume(s)
			Price(s)	Volume(s)
			25.00 pence	1,000,000
d)	Aggregated information		N/A - Single transaction
e)	Date of the transaction	21 December 2021
f)	Place of the transaction	Outside a trading venue

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Dr Christopher Hand
2	Reason for the notification
a)	Position/status	Chairman
b)	Initial notification /Amendment	Initial Notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Abingdon Health plc
b)	LEI	213800XFI4WV3FBILO20
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument	Ordinary Shares of 0.025 pence each
	Identification code	GB00BLF79J41
b)	Nature of the transaction	Purchase of Ordinary Shares
c)	Price(s) and volume(s)
			Price(s)	Volume(s)
			25.00 pence	999,599
d)	Aggregated information		N/A - Single transaction
e)	Date of the transaction	21 December 2021
f)	Place of the transaction	Outside a trading venue

 

END

 

 

DSHVFLBLFLLXFBV